Login to Your Account



Search

Search results

Clinic roundup

Advaxis Inc. , of Princeton, N.J, said it plans to start a clinical development program with ADXS-cHER2, an immunotherapy candidate designed to target the HER2 oncogene, for the treatment of pediatric osteosarcoma. (BioWorld-Today-2014-0 ...

BioWorld Today - Staff - 2014-05-06 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

UCB SA , of Brussels, Belgium, reported results from the PRECiSE 3 seven-year open-label extension trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. (Bi ...

BioWorld Today - Staff - 2014-05-06 00:00 - 0 comments - 0 attachments

Clinic roundup

Ruthigen Inc. , of Santa Rosa, Calif., said it submitted an investigational new drug application for lead candidate RUT58-60, a broad-spectrum anti-infective drug for prophylactic use during invasive medical procedures. (BioWorld-Today-2014- ...

BioWorld Today - Staff - 2014-05-05 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

CSL Behring Ltd. , of King of Prussia, Pa., said the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the efficacy, safety and pharmacokinetics of its investigational recombinant factor VIII single chain (rVIII-Sin ...

BioWorld Today - Staff - 2014-05-05 00:00 - 0 comments - 0 attachments

Clinic roundup

Isis Pharmaceuticals Inc. , of Carlsbad, Calif., said phase II results of ISIS-APOCIII in patients with high triglycerides and type 2 diabetes show it achieved statistically significant average mean percent reduction from baseline of 88 percent (p = ...

BioWorld Today - Staff - 2014-05-02 00:00 - 0 comments - 0 attachments

Clinic roundup

Adamas Pharmaceuticals Inc., of Emeryville, Calif., reported the 340-mg dose of ADS-5102 resulted in a statistically significant improvement in overall Parkinson's disease clinical status, including levodopa-induced dyskinesia, when compared with pl ...

BioWorld Today - Staff - 2014-05-01 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Teva Pharmaceutical Industries Ltd ., of Jerusalem, reported positive results from a pivotal phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties ...

BioWorld Today - Staff - 2014-05-01 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Upsher-Smith Laboratories Inc. , of Maple Grove, Minn., reported phase I data for USL261 (investigational intranasal midazolam) in patients with epilepsy were presented at the 66th Annual American Academy of Neurology (AAN) meeting in Philadelphia. ...

BioWorld Today - Staff - 2014-04-30 00:00 - 0 comments - 0 attachments

Clinic roundup

Biogen Idec Inc. , of Cambridge, Mass., announced two-year phase III data from the ADVANCE trial for Plegridy (peginterferon beta-1a) in relapsing multiple sclerosis (MS) patients. The data, which were presented at the 66th American Academy of Neurol ...

BioWorld Today - Staff - 2014-04-30 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Sanofi Pasteur, the vaccines division of Sanofi SA , of Paris, said the first of two pivotal phase III efficacy studies with its dengue vaccine candidate has achieved its primary clinical endpoint. The study showed a reduction of 56 percent of dengue ...

BioWorld Today - Staff - 2014-04-29 00:00 - 0 comments - 0 attachments